Multiple Sclerosis. Everything you need to know

It's also worth noting that the Plegridy trials leaned heavily on detailed MRI metrics. By the 2010s, high-resolution tomographs sat in every local clinic, and ignoring this data stream was impossible. While older interferons made vague references to "reducing spot counts," Plegridy arrived with ironclad data metrics: injecting the drug once every 2 weeks drove a 67% reduction in new or expanding T2 lesions and slashed contrast-accumulating hotspots by a staggering 86%. On paper, Plegridy practically guaranteed MS patients a flawless, fully functional life straight into old age—at least, as long as you evaluated success purely by looking at an MRI screen.

In total, over the span of 20 years, the market engineered three generations of interferon (beta-1b, beta-1a, and pegylated beta-1a) and deployed two delivery tracks (intramuscular and subcutaneous). An attentive reader will notice that we haven't said a word about an intramuscular track for pegylated interferons—don't worry, the strategists at Biogen spotted that running room too. In February 2021, they secured FDA approval for Plegridy IM (Intramuscular). This new track cut injection-site skin necrosis from 32.1% down to 14.4%. Deep muscle tissue is packed with blood vessels, allowing the massive protein molecule to wash out into the system before it can cause the skin overlaying it to rot away. Most importantly, this fresh delivery track allowed Biogen to secure a brand-new patent, extending their corporate monopoly over pegylated interferons for years.

As far as my research into global pharmaceutical registries shows, no company on earth is currently funding the development of next-generation interferons for multiple sclerosis. The scientific lifecycle of the molecule has topped out. As soon as the foundational patents began to expire, the pharmaceutical giants completely lost interest in the compound. The absolute victor of the "Interferon War" is Biogen, with cumulative sales hitting a mountain of roughly $42–$43 billion. Merck/Serono takes second place with $24 billion, and the trailblazers at Chiron/Bayer walk away with third place at roughly $18 billion.

The master key to the multi-decade popularity of interferons is that patients almost never buy them with their own money. In the US, insurance conglomerates foot the bill; in Europe, the state insurance funds take the hit; in Russia, the federal budget absorbs the cost. The illusion of a "free lunch" is the foundational component of interferon's longevity. Less than 5% of patients worldwide drain their personal savings accounts to buy these shots, and when they do, it’s usually for a very brief window. When interferons completely fail to protect a patient from creeping disability or fresh relapses, the human mind rationalizes the failure away by reminding itself that the medicine didn't cost them a dime. You don't look a gift horse in the mouth. But if you actually bought that horse with your own hard-earned cash, a single glance under its lip would reveal it has no teeth whatsoever.

PS: The disastrous regulatory compromise signed by the FDA in 1995 regarding another class of drugs allowed Purdue Pharma to market an opioid-based pill called OxyContin to the general public for "moderate pain." What followed is brilliantly laid out in one of the best shows of recent years—Dopesick